Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | POLB | P06746 | 3/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.41 |
| ▸ | PLK1 | P53350 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2824926 | 0.85 | ALDH1A1 (0.65) | KDM4EALDH1A1POLBMAPTSMN1; SMN2 | |
| SCHEMBL26105379 | 0.81 | GAA (0.46) | KDM4EALDH1A1POLBMAPTSMN1; SMN2 | |
| SCHEMBL27033898 | 0.81 | ALDH1A1 (0.48) | KDM4EALDH1A1POLBMAPTSMN1; SMN2 | |
| SCHEMBL27033354 | 0.81 | LMNA (0.57) | KDM4EALDH1A1POLBMAPTSMN1; SMN2 | |
| SCHEMBL13837880 | 0.81 | KMT2A (0.47) | KDM4EALDH1A1POLBMAPTSMN1; SMN2 | |
| SCHEMBL23520538 | 0.81 | KDM4E (0.44) | KDM4EALDH1A1POLBMAPTSMN1; SMN2 | |
| SCHEMBL4591133 | 0.80 | KDM4E (1.00) | KDM4EALDH1A1POLBMAPTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL26105494 | 0.80 | GAA (0.44) | KDM4EALDH1A1POLBMAPTSMN1; SMN2 | |
| SCHEMBL15468963 | 0.79 | MAPT (0.44) | KDM4EALDH1A1POLBMAPTSMN1; SMN2 | |
| SCHEMBL2825710 | 0.78 | KDM4E (0.65) | KDM4EALDH1A1POLBMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2880033-B1 | CYCLIC UREA- OR LACTAM-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA LP (US) | 2020-06-17 | — | — | EP | disclosed |
| US-9085561-B2 | Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators | PURDUE PHARMA L.P. (US) | 2015-07-21 | — | — | US | disclosed |
| US-8921243-B2 | Fabrics comprising a photocatalyst to produce singlet oxygen from ambient oxygen | VENTANA RESEARCH CORPORATION | 2014-12-30 | — | — | US | disclosed |
| US-8921243-B2 | Fabrics comprising a photocatalyst to produce singlet oxygen from ambient oxygen | VENTANA RESEARCH CORPORATION | 2014-12-30 | — | — | US | disclosed |
| US-8481446-B2 | Chemically-resistant coating composition | VENTANA RESEARCH CORPORATION | 2013-07-09 | — | — | US | disclosed |
| US-8481446-B2 | Chemically-resistant coating composition | VENTANA RESEARCH CORPORATION | 2013-07-09 | — | — | US | disclosed |
| US-20120135651-A1 | Fabrics Comprising a Photocatalyst to Produce Singlet Oxygen from Ambient Oxygen | VENTANA RESEARCH CORPORATION | 2012-05-31 | — | — | US | disclosed |
| US-20120135651-A1 | Fabrics Comprising a Photocatalyst to Produce Singlet Oxygen from Ambient Oxygen | VENTANA RESEARCH CORPORATION | 2012-05-31 | — | — | US | disclosed |
| WO-2011142838-A2 | CHEMICALLY-RESISTANT COATING COMPOSITION | LOMBARID JOHN L (US) | 2011-11-17 | — | — | WO | disclosed |
| US-20100279850-A1 | CHEMICALLY-RESISTANT COATING COMPOSITION | VENTANA RESEARCH CORPORATION | 2010-11-04 | — | — | US | disclosed |
| US-20100279850-A1 | CHEMICALLY-RESISTANT COATING COMPOSITION | VENTANA RESEARCH CORPORATION | 2010-11-04 | — | — | US | disclosed |
| WO-2010118180-A1 | FABRICS COMPRISING A PHOTOCATALYST TO PRODUCE SINGLET OXYGEN FROM AMBIENT OXYGEN | LOMBARDI JOHN L (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279850-A1 | CHEMICALLY-RESISTANT COATING COMPOSITION | DNMT1, VCL, DNMT3L | KDM4E 173/4885ALDH1A1 1103/4885POLB 1463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.